Lorazepam
| Lorazepam | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 321.20 g/mol [1] |
| Melting point | 192-194 [1] |
| Boiling point | 533.8 °C at 760 mm Hg [1] |
| Solubility | 80 mg/L [1] |
| Predicted LogP | 2.4 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C15H10Cl2N2O2 |
| IUPAC name | 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one |
| SMILES | C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl |
| InChI | InChI=1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20) |
| InChIKey | DIWRORZWFLOCLC-UHFFFAOYSA-N |
| CAS number | 846-49-1 |
| UNII | O26FZP769L |
| PubChem CID | 3958 |
| Pharmacokinetics[] | |
|---|---|
| Onset | Intravenous therapy: 1–5 minutes, Intramuscular injection: 15–30 minutes, Oral administration: 20–30 minutes[3] |
| Elimination half-life | 10–20 hours[4][5][6] |
| Duration of action | IV/IM: 12–24 hours, PO: 6–8 hours[3] |
| Metabolism | Liver glucuronidation |
| Excretion | Kidney |
| Routes of administration | By mouth, intramuscular, intravenous, transdermal |
| Dependence liability | High[7] |
| Addiction liability | Moderate[8][9] |
Lorazepam (also known as Ativan, Temesta, Loraz, Wypax, Almazine, Anxiedin, Lorabenz, Orfidal, Lorazepam Intensol or Wy-4036) is a substance of the aniline and benzodiazepine class.
Chemistry
Stereochemistry []
Lorazepam is a racemic mixture of the enantiomers (optical activity ( + / - )).
Druglikeness
Lipinski's rule of five
Lorazepam matches Lipinski's rule of five.Reagents
There are currently 4 reagent-interactions on DrugsPRO
| Reagent | Color change | Description |
|---|---|---|
| Marquis | no color change | |
| Mecke | no color change | |
| Mandelin | no color change | |
| Zimmermann | no change / faint yellow |
Pharmacology
ATC Classification
- nervous system (N)
- psycholeptics (N05)
- anxiolytics (N05B)
- benzodiazepine derivatives (N05BA)
- (N05BA06)
- lorazepam (N05BA06)
MeSH Classification
- anticonvulsants (M0001382)
- antiemetics (M0001391)
- hypnotics and sedatives (M0010885)
- anti-anxiety agents (M0021771)
- gaba modulators (M0028093)
Mechanism of action []
Lorazepam allosterically binds on the benzodiazepine receptors in the post-synaptic GABA-A ligand-gated chloride channel in different sites of the central nervous system (CNS). This binding will result in an increase on the GABA inhibitory effects which is translated as an increase in the flow of chloride ions into the cell causing hyperpolarization and stabilization of the cellular plasma membrane. According to the binding site of lorazepam, we can observe different activities as the binding in the amygdala is known to help mainly in anxiety disorders while the binding in the cerebral cortex helps in seizure disorders. [1]
Interactions []
Interaction mechanisms documented in KEGG DRUG (number of interacting drugs):
| GABRA1 | shared target | 31 |
|---|---|---|
| GABRA2 | shared target | 29 |
| GABRA3 | shared target | 29 |
| GABRA4 | shared target | 29 |
| GABRA5 | shared target | 29 |
| GABRA6 | shared target | 29 |
| GABRB1 | shared target | 29 |
| GABRB2 | shared target | 29 |
| GABRB3 | shared target | 29 |
| GABRD | shared target | 29 |
| GABRE | shared target | 29 |
| GABRG1 | shared target | 29 |
| GABRG2 | shared target | 29 |
| GABRG3 | shared target | 29 |
| GABRP | shared target | 29 |
| GABRQ | shared target | 29 |
Medical side effects []
120 side effects listed on drug labels in SIDER 4.1 (lorazepam).
- Dizziness
- Asthenia
- Fatigue
- Somnolence
- Drowsiness
- Balance disorder
- Respiratory failure
- Hypoventilation
- Apnoea
- Headache
- Hypoxia
- Hypochromic anaemia
- Leukocytosis
- Thrombocytosis
- Acidosis
- Ataxia
- Coma
- Infection
- Confusional state
- Feeling abnormal
- Cystitis
- Bladder pain
- Cystitis noninfective
- Hallucination
- Hyperventilation
- Myoclonus
- Nausea
- Convulsion
- Salivary hypersecretion
- Tremor
- Vomiting
- Chills
- Stupor
- Depressed level of consciousness
- CNS depression NOS
- Agitation
- Excitement
- Excitability
- Injection site reaction
- Liver function test abnormal
- Blood alkaline phosphatase increased
- Thinking abnormal
- Mental disability
- Brain oedema
- Hypertension
- Hypotension
- Amnesia
- Amnesia transient
- Arrhythmia
- Coagulopathy
- Delirium
- Gastrointestinal haemorrhage
- Cardiac arrest
- Atrioventricular block
- Pulmonary hypertension
- Nervousness
- Tension
- Neuroleptic malignant syndrome
- Pericardial effusion
- Pneumothorax
- Pulmonary oedema
- Tachycardia
- Thrombocytopenia
- Urinary incontinence
- Ventricular arrhythmia
- Pulmonary haemorrhage
- Hepatocellular injury
- Liver injury
- Respiratory arrest
- Bradycardia
- Sleep apnoea syndrome
- Paralysis
- Aggression
- Agranulocytosis
- Obstructive airways disorder
- Alopecia
- Constipation
- Diplopia
- Dysarthria
- Slurred speech
- Osteoarthritis
- Dermatitis
- Rash
- Gangrene
- Hostility
- Hypersensitivity
- Hyponatraemia
- Body temperature decreased
- Hypothermia
- Inappropriate antidiuretic hormone secretion
- Irritability
- Jaundice
- Lethargy
- Pain
- Pancytopenia
- Psychotic disorder
- Sleep disorder
- Vertigo
- Dry mouth
- Arterial spasm
- Injection site pain
- Disorientation
- Memory impairment
- Anterograde amnesia
- Extrapyramidal disorder
- Respiratory depression
- Pulmonary function test decreased
- Euphoric mood
- Erectile dysfunction
- Erythema
- Mania
- Vision blurred
- Suicidal ideation
- Disinhibition
- Gastrointestinal disorder
- Application site pain
- Instillation site pain
- Sedation
- Visual impairment
- Hypersomnia
Indications
- Anxiety
- Anxiety disorder
- Anxiety neurosis
- Depressive symptom
- Drowsiness
- Insomnia
- Status epilepticus
- Tension
Subjective effects []
| 0xea / Lorazepam [] | |
|---|---|
Routes:
| |
| a1ko / Lorazepam [] | |
|---|---|
Routes:
| |
| alina / Lorazepam [] | |
|---|---|
Routes:
| |
| bonzi / Lorazepam [] | |
|---|---|
Routes:
| |
| emily / Lorazepam [] | |
|---|---|
Routes:
| |
| magnus / Lorazepam [] | |
|---|---|
Routes:
| |
| nervewing / Lorazepam [] | |
|---|---|
| Pilz / Lorazepam [] | |
|---|---|
Routes:
| |
Experience reports
- "My psychedelic experience with cannabis" by kmcel624 (16 upvotes)
- "3 gram Golden teacher challenging trip report" by AustinEly (15 upvotes)
- "First psilocybin trip" by TBKmama (13 upvotes)
- "Changa + 4-HO-MET: No colors, no fractals… just a terrifyingly real trip" by Electronic_Dish9467 (7 upvotes)
- "DMT + 4-HO-MET: No colors, no fractals… just a terrifyingly real trip" by Electronic_Dish9467 (3 upvotes)
- "Methamphetamine Trip Report (X-Post From r/drugs)" by Drugthrowaway123654 (3 upvotes)
- "Weed + Ativan + Vodka + Xanax" by lolnoscopedtf (2 upvotes)
- "A Lackluster Venture In to Barb-Land" by Lysergedelia (1 upvotes)
- "Promethazine+lorazepam= a fun little mixture" by FajitaCheetah (1 upvotes)
Legal status []
- Australia: Lorazepam is a Schedule 4.[10]
- Brazil: Lorazepam is a B1.[11]
- Canada: Lorazepam is a Schedule IV.
- Germany: Lorazepam is Prescription only/Anlage III.
- United Kingdom: Lorazepam is Prescription only.[12][13]
- United States: Lorazepam is a Schedule IV under the "Controlled Substances Act".[14][15][16]
- Other: Lorazepam is a SE: Förteckning IV , Rx-only.[17][18][19]
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 3958, Lorazepam. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/3958
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Lorazepam. UNII: O26FZP769L. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/O26FZP769L
About lorazepam. nhs.uk. 17 February 2023. https://www.nhs.uk/medicines/lorazepam/about-lorazepam/
Greenblatt DJ, Shader RI, Franke K, Maclaughlin DS, Harmatz JS, Allen MD, Werner A, Woo E. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. Journal of Pharmaceutical Sciences. 1991; 68(1):57–63. PMID 31453. https://doi.org/10.1002/jps.2600680119
Greenblatt DJ, von Moltke LL, Ehrenberg BL, Harmatz JS, Corbett KE, Wallace DW, Shader RI. Kinetics and dynamics of lorazepam during and after continuous intravenous infusion. Critical Care Medicine. 2000; 28(8):2750–2757. PMID 10966246. https://doi.org/10.1097/00003246-200008000-00011
Papini O, da Cunha SP, da Silva Mathes Ado C, Bertucci C, Moisés EC, de Barros Duarte L, de Carvalho Cavalli R, Lanchote VL. Kinetic disposition of lorazepam with a focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples. Journal of Pharmaceutical and Biomedical Analysis. 2006; 40(2):397–403. PMID 16143486. https://doi.org/10.1016/j.jpba.2005.07.021
Edmunds M, Mayhew M. Pharmacology for the Primary Care Provider. Mosby. 2013. https://books.google.com/books?id=8FwdEsvnw8oC&pg=PA545
Clinical Addiction Psychiatry. Cambridge University Press. 2010. https://books.google.com/books?id=xD-R7Z27UBEC&pg=PA156
Ries RK. Principles of addiction medicine. Wolters Kluwer/Lippincott Williams & Wilkins. 2009. https://books.google.com/books?id=j6GGBud8DXcC&pg=PA106
Lorazepam-AFT (AFT Pharmaceuticals Pty Ltd). Australian Government – Department of Health and Aged Care. https://www.tga.gov.au/resources/prescription-medicines-registrations/lorazepam-aft-aft-pharmaceuticals-pty-ltd
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Lorazepam Macure 4mg/ml solution for injection Summary of Product Characteristics (SmPC). (emc). 22 April 2021. https://www.medicines.org.uk/emc/product/12318/smpc
Lorazepam Aristo 1 mg tablets Summary of Product Characteristics (SmPC). (emc). 9 March 2020. https://www.medicines.org.uk/emc/product/11146/smpc
Ativan- lorazepam tablet. DailyMed. 13 January 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89057c93-8155-4040-acec-64e877bd2b4c
Ativan- lorazepam injection. DailyMed. 7 April 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fc0e987-61c9-40c4-b0d5-fcea07c8733e
Loreev XR- lorazepam capsule, extended-release. DailyMed. 20 January 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=227734c1-bf01-9607-73ea-5a1f38a89bd9
Temesta® (Tablett 1 mg) • Produktresumé | FASS Vård. Fass.se. https://fass.se/health/product/19800125000040/smpc
Lorazepam Macure 4 mg/ml, solution for injection. European Medicines Agency (EMA). 27 June 2024. https://www.ema.europa.eu/en/medicines/human/referrals/lorazepam-macure-4-mg-ml-solution-injection
List of nationally authorised medicinal products: Active substance: lorazepam. European Medicines Agency (EMA). 1 October 2020. https://www.ema.europa.eu/en/documents/psusa/lorazepam-list-nationally-authorised-medicinal-products-psusa00001909202001_en.pdf
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 10:19:13 |
| drugspro | ok | 2026-11-20 10:19:09 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 10:19:09 |
| gsrs | ok | 2026-11-20 10:19:09 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014332) | 2026-11-20 10:19:09 |
| kegg | ok | 2026-11-20 10:19:11 |
| pubchem | ok | 2026-11-20 10:19:08 |
| ok | 2026-11-20 10:19:08 | |
| sider | ok | 2026-11-20 10:19:09 |
| structure | ok | 2026-11-20 10:19:08 |
| wikipedia | ok | 2026-11-20 10:19:09 |